rifampin and Bronchial-Diseases

Bronchoscopic balloon dilation is a common method in the treatment of bronchostenosis but it is not an effective treatment due to its short dilating time (3 minutes) and low pressure (<3atm). Until recently, the reported highest dilating pressure was ≤6atm; however, this is not enough pressure to dilate a bronchostenosis because of the resistance of the bronchus. We hypothesized that higher dilating pressure (up to 14atm) with longer dilating time (40 minutes) may make bronchoscopic balloon dilation treatment more effective according to the blood vessel dilating method. Therefore, we designed this new bronchoscopic balloon dilation method for treating bronchostenosis, particularly in cases caused by bronchial tuberculosis.. A 23-year-old Chinese woman presented with right middle segmental bronchostenosis caused by bronchial tuberculosis. She was informed of the surgical procedure and she provided informed consent. After taking anti-bronchial tuberculosis drugs for 2 months, she underwent our new bronchoscopic balloon dilation treatment (dilating time, 40 minutes; pressure, 14atm). After anti-bronchial tuberculosis treatment for 13 months, her intermediate bronchus was observed with videobronchoscopy again and no re-stenosis was seen. Furthermore, a computed tomography scan revealed that her right lower lobe and right middle lobe had reopened. No complications occurred in the patient.. The novel high-handed videobronchoscopic balloon dilation method was safe and effective for treating this patient with bronchostenosis caused by bronchial tuberculosis.

Topics: Antitubercular Agents; Bronchial Diseases; Bronchoscopy; Constriction, Pathologic; Dilatation; Ethambutol; Female; Humans; Isoniazid; Lung; Pyrazinamide; Radiography; Rifampin; Treatment Outcome; Tuberculosis, Pulmonary; Young Adult

Rifamethoprim is a new formulation containing rifampicin and trimethoprim. Its efficacy was studied in the treatment of a group of patients with various nonspecific diseases of the lungs. It was shown to be highly active against a broad spectrum of pathogens. With inclusion of trimethoprim to the formulation it appeared possible to markedly lower the bacterial ability to develop resistance to rifampicin, which solved the problem of long-term antibiotic use. The unique pharmacokinetic properties of rifampicin such as its capacity to penetrating into the sputum, lung tissues and cells make rifamethoprim be the drug of optimal choice in the treatment of respiratory diseases.

Topics: Acute Disease; Anti-Bacterial Agents; Bronchial Diseases; Chronic Disease; Drug Combinations; Drug Therapy, Combination; Humans; Lung Diseases; Rifampin; Trimethoprim

Topics: Aged; Bronchial Diseases; Bronchoscopy; Ethambutol; Female; Humans; Isoniazid; Mycobacterium tuberculosis; Radiography; Rifampin; Sputum; Tracheal Diseases; Tuberculosis

Topics: Bronchial Diseases; Drug Resistance, Microbial; Haemophilus influenzae; Humans; Neisseria; Respiratory Tract Infections; Rifampin; Streptococcus; Streptococcus pneumoniae

Topics: Bronchial Diseases; Chloramphenicol; Humans; Lung Diseases; Microbial Sensitivity Tests; Pseudomonas Infections; Rifampin; Staphylococcal Infections; Streptococcal Infections; Tetracycline

Topics: Bronchial Diseases; Chloramphenicol; Drug Resistance, Microbial; Humans; In Vitro Techniques; Novobiocin; Rifampin; Sputum